Navigation Links
Twenty Years of Malaria Research: Outcomes and Perspectives

The Shoklo Malaria Research Unit (SMRU), Thailand, will be hosting a scientific seminar in Mae Sot on 28 December entitled "Twenty Years of Malaria Research: Outcomes and Perspectives" attended by internationally-renowned experts and featuring talks and debates on a variety of topics related to malaria, from epidemiology to therapeutics and from immunity to socio-economics.

As the Shoklo Malaria Research Unit (SMRU) in Mae Sot, Thailand, which borders Burma, celebrates its twentieth anniversary, its Director, Professor Fran├žois Nosten, is able to reflect on the success of the unit, which is based amongst the region's refugee camps. The currently recommended malaria therapies (based on drug combinations including an artemisinin derivative) are the result of research carried out at SMRU, which is part of the Wellcome Trust's Major Overseas Programme in Thailand. Professor Nosten is amongst the top ten most-cited researchers in malaria research and has been a key player in the fight against drug-resistant strains of the parasite.

Opening in 1986 at Nosten's home, the research unit moved to Shoklo in 1989, the largest of the refugee camps on the border of Thailand and Burma, where 9,000 Karen refugees from across the border were housed. The focus of the research was to study the efficacy of malaria drug treatments in pregnant women and in children.

The unit was forced to move to its current location in Mae Sot in 1996 one year after an attack by guerrillas from the Democratic Karen Buddhist Army, targeting foreign aid workers in an attempt to force the refugees to return to Burma. During the attack, Professor Nosten and his colleague Rose McGready had been forced to hide in the jungle.

Now, Professor Nosten is assisted in his work by Thai nationals from the region, including a number of local Karen and Burmese who received training by the SMRU team. In addition to studying malaria drug treatments for pregnant women, the unit has carri ed out crucial research into artemisinin combination therapies (ACTs) aimed at combating the rapid rise in drug-resistance. The unit has carried out the largest number of drug trials in malaria and research at the unit has been influential in changing WHO guidelines for malaria drug treatment.

The reduction in the number of malaria cases has allowed the unit to focus on other health issues such as respiratory diseases. In addition, a surveillance network established in 1995 to monitor malaria infection in the camps along the border has now received funding to track the development of the avian influenza virus.


Source:Wellcome Trust

Related biology news :

1. Twenty of worlds 162 grouper species threatened with extinction
2. New Clues Add 40,000 Years to Age of Human Species
3. Measles Deaths Worldwide Drop By Nearly 40% Over Five Years
4. A New Species of Monkey is Discovered in Tanzania: The First in Africa for More Than 20 Years
5. Malaria mechanism revealed
6. Malaria killing a million a year
7. Malaria parasites develop in lymph nodes
8. Malaria, potato famine pathogen share surprising trait
9. Malaria vaccine prompts victims immune system to eliminate parasite from mosquitoes
10. Malaria treatment efficacy compromised in certain HIV-positive patients
11. Malaria may fuel spread of HIV in sub-Saharan Africa
Post Your Comments:

(Date:11/19/2015)... NEW YORK , Nov. 19, 2015  Although ... the market is dominated by a few companies, according ... Qiagen. These companies own 51% of the market share of ... report, The World Market for Molecular Diagnostic ... "The market is still controlled by one ...
(Date:11/17/2015)... 2015  Vigilant Solutions announces today that Mr. ... Directors. --> --> ... the partnership at TPG Capital, one of the largest ... Billion in revenue.  He founded and led TPG,s Operating ... companies, from 1997 to 2013.  In his first role, ...
(Date:11/12/2015)... 11, 2015   Growing need for low-cost, ... has been paving the way for use of ... discrete analytes in clinical, agricultural, environmental, food and ... used in medical applications, however, their adoption is ... to continuous emphasis on improving product quality and ...
Breaking Biology News(10 mins):
(Date:11/25/2015)... , Nov. 25, 2015 /PRNewswire/ - Aeterna Zentaris ... that its business and prospects remain fundamentally strong ... Zoptrex™ (zoptarelin doxorubicin) recently received DSMB recommendation to ... completion following review of the final interim efficacy ... 2 Primary Endpoint in men with heavily pretreated ...
(Date:11/24/2015)... LUMPUR, Malaysia , Nov. 24, 2015 /PRNewswire/ ... global contract research organisation (CRO) market. The trend ... result in lower margins but higher volume share ... increased capacity and scale, however, margins in the ... Research Organisation (CRO) Market ( ), ...
(Date:11/24/2015)... ... 2015 , ... Copper is an essential micronutrient that all ... copper is also toxic to cells. With a $1.3 million award from the ... a systematic study of copper in the bacteria Pseudomonas aeruginosa (P. aeruginosa), a ...
(Date:11/24/2015)... PA (PRWEB) , ... November 24, 2015 , ... This ... entrepreneurs at competitive events in five states to develop and pitch their BIG ideas ... projects from each state are competing for votes to win the title of SAP's ...
Breaking Biology Technology: